WO2007075555A2 - Combination of an h3 antagonist/inverse agonist and an appetite suppressant - Google Patents
Combination of an h3 antagonist/inverse agonist and an appetite suppressant Download PDFInfo
- Publication number
- WO2007075555A2 WO2007075555A2 PCT/US2006/048223 US2006048223W WO2007075555A2 WO 2007075555 A2 WO2007075555 A2 WO 2007075555A2 US 2006048223 W US2006048223 W US 2006048223W WO 2007075555 A2 WO2007075555 A2 WO 2007075555A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- aryl
- group
- independently selected
- alkoxy
- Prior art date
Links
- 239000002830 appetite depressant Substances 0.000 title claims abstract description 41
- 239000003395 histamine H3 receptor antagonist Substances 0.000 title claims description 26
- 229940125425 inverse agonist Drugs 0.000 title claims description 20
- 208000008589 Obesity Diseases 0.000 claims abstract description 37
- 235000020824 obesity Nutrition 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000005557 antagonist Substances 0.000 claims abstract description 28
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims abstract description 26
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960004425 sibutramine Drugs 0.000 claims abstract description 19
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 180
- 150000001875 compounds Chemical class 0.000 claims description 97
- 239000000203 mixture Substances 0.000 claims description 88
- 125000003118 aryl group Chemical group 0.000 claims description 79
- 229910052739 hydrogen Inorganic materials 0.000 claims description 74
- 125000001424 substituent group Chemical group 0.000 claims description 65
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 63
- 229910052757 nitrogen Inorganic materials 0.000 claims description 62
- 125000001072 heteroaryl group Chemical group 0.000 claims description 60
- 229910052799 carbon Inorganic materials 0.000 claims description 57
- -1 - CF3 Chemical group 0.000 claims description 53
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 52
- 125000003545 alkoxy group Chemical group 0.000 claims description 52
- 229910052736 halogen Inorganic materials 0.000 claims description 50
- 150000002367 halogens Chemical class 0.000 claims description 50
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 43
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 42
- 125000005843 halogen group Chemical group 0.000 claims description 40
- 239000001257 hydrogen Substances 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 38
- 125000004432 carbon atom Chemical group C* 0.000 claims description 32
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 31
- 239000012453 solvate Substances 0.000 claims description 31
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 30
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
- 239000003623 enhancer Substances 0.000 claims description 28
- 230000037323 metabolic rate Effects 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
- 229940002612 prodrug Drugs 0.000 claims description 23
- 239000000651 prodrug Substances 0.000 claims description 23
- 125000006413 ring segment Chemical group 0.000 claims description 23
- 150000002148 esters Chemical class 0.000 claims description 22
- 125000002947 alkylene group Chemical group 0.000 claims description 19
- 229940125708 antidiabetic agent Drugs 0.000 claims description 17
- 239000003472 antidiabetic agent Substances 0.000 claims description 17
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 102000004877 Insulin Human genes 0.000 claims description 15
- 108090001061 Insulin Proteins 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 15
- 229940125396 insulin Drugs 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 229960003562 phentermine Drugs 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 229940122355 Insulin sensitizer Drugs 0.000 claims description 14
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 14
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 14
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical group CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 claims description 14
- 229960003015 rimonabant Drugs 0.000 claims description 14
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 14
- 229960004394 topiramate Drugs 0.000 claims description 14
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 13
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 12
- 239000000883 anti-obesity agent Substances 0.000 claims description 12
- 229940125710 antiobesity agent Drugs 0.000 claims description 12
- 229960002855 simvastatin Drugs 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 11
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 10
- 229940100389 Sulfonylurea Drugs 0.000 claims description 10
- 229960002965 pravastatin Drugs 0.000 claims description 10
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 9
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 9
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000012190 activator Substances 0.000 claims description 8
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 229960004844 lovastatin Drugs 0.000 claims description 8
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 8
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 8
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 7
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 125000004450 alkenylene group Chemical group 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 7
- 229960005370 atorvastatin Drugs 0.000 claims description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 7
- 125000002757 morpholinyl group Chemical group 0.000 claims description 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 7
- 125000004193 piperazinyl group Chemical group 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 239000011593 sulfur Substances 0.000 claims description 7
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 6
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 6
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 5
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 5
- 229940122199 Insulin secretagogue Drugs 0.000 claims description 5
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 5
- 229950004994 meglitinide Drugs 0.000 claims description 5
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical group O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 4
- 229960003765 fluvastatin Drugs 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 3
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 62
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 59
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 33
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 31
- 150000002431 hydrogen Chemical class 0.000 claims 29
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 18
- 125000001153 fluoro group Chemical group F* 0.000 claims 17
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 11
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 125000002393 azetidinyl group Chemical group 0.000 claims 6
- 125000003386 piperidinyl group Chemical group 0.000 claims 6
- 150000001721 carbon Chemical group 0.000 claims 4
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 229960000672 rosuvastatin Drugs 0.000 claims 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 2
- 125000005306 thianaphthenyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- MZAGXDHQGXUDDX-JSRXJHBZSA-N (e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/C(N)=O MZAGXDHQGXUDDX-JSRXJHBZSA-N 0.000 claims 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
- 239000000556 agonist Substances 0.000 abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 11
- 208000035475 disorder Diseases 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 10
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- PWDLDBWXTVILPC-WGAVTJJLSA-N CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 Chemical compound CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 PWDLDBWXTVILPC-WGAVTJJLSA-N 0.000 abstract description 3
- 0 C*C(C1)C2CC1C(*)C2 Chemical compound C*C(C1)C2CC1C(*)C2 0.000 description 28
- 102000005962 receptors Human genes 0.000 description 25
- 108020003175 receptors Proteins 0.000 description 25
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- 239000002464 receptor antagonist Substances 0.000 description 12
- 229940044551 receptor antagonist Drugs 0.000 description 12
- 125000000304 alkynyl group Chemical group 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000002469 receptor inverse agonist Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 5
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 125000005275 alkylenearyl group Chemical group 0.000 description 4
- 125000005038 alkynylalkyl group Chemical group 0.000 description 4
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 4
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 4
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 230000000742 histaminergic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000004384 Histamine H3 receptors Human genes 0.000 description 3
- 108090000981 Histamine H3 receptors Proteins 0.000 description 3
- 241000009328 Perro Species 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 229940030600 antihypertensive agent Drugs 0.000 description 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960004580 glibenclamide Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 2
- 102000030595 Glucokinase Human genes 0.000 description 2
- 108010021582 Glucokinase Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 2
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 description 2
- 101710125793 Hydroxycarboxylic acid receptor 2 Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 241000534944 Thia Species 0.000 description 2
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000005042 acyloxymethyl group Chemical group 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960001761 chlorpropamide Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 229960004346 glimepiride Drugs 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 229960001110 miglitol Drugs 0.000 description 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 2
- 229960000698 nateglinide Drugs 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 229960002354 repaglinide Drugs 0.000 description 2
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000035924 thermogenesis Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229960001729 voglibose Drugs 0.000 description 2
- 229940072168 zocor Drugs 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- FOZFSEMFCIPOSZ-SPCKQMHLSA-N (2r,3r,4r,5s)-2-(hydroxymethyl)-1-[[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl]piperidine-3,4,5-triol;trihydrate Chemical compound O.O.O.O[C@H]1[C@H](O)[C@@H](O)[C@@H](OC)O[C@@H]1CN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1.O[C@H]1[C@H](O)[C@@H](O)[C@@H](OC)O[C@@H]1CN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 FOZFSEMFCIPOSZ-SPCKQMHLSA-N 0.000 description 1
- PAORVUMOXXAMPL-SECBINFHSA-N (2s)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-SECBINFHSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- 125000005851 1-(N-(alkoxycarbonyl)amino)ethyl group Chemical group 0.000 description 1
- 125000005846 1-(alkanoyloxy)ethyl group Chemical group 0.000 description 1
- 125000005848 1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- 125000005847 1-methyl-1-(alkanoyloxy)-ethyl group Chemical group 0.000 description 1
- 125000005849 1-methyl-1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- IDFWXBZNSWSVIP-UHFFFAOYSA-N C/[O]=C(/C1CCN(Cc2cccc(O)c2)CC1)\N(CC1)CCC1Oc(c(F)cc(F)c1)c1F Chemical compound C/[O]=C(/C1CCN(Cc2cccc(O)c2)CC1)\N(CC1)CCC1Oc(c(F)cc(F)c1)c1F IDFWXBZNSWSVIP-UHFFFAOYSA-N 0.000 description 1
- XUDQYYXBMCEDAQ-UHFFFAOYSA-N C/[O]=S(\C)/c(cc1)cc2c1[n](C(CC1)CCN1C(C1CCN(Cc3ccnnc3)CC1)=O)c(-c1ncccc1)n2 Chemical compound C/[O]=S(\C)/c(cc1)cc2c1[n](C(CC1)CCN1C(C1CCN(Cc3ccnnc3)CC1)=O)c(-c1ncccc1)n2 XUDQYYXBMCEDAQ-UHFFFAOYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 229940124802 CB1 antagonist Drugs 0.000 description 1
- CXKWGHDNQISAKH-UHFFFAOYSA-N CC(C)Oc1nc(cc(cc2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnncc2)CC1)=O Chemical compound CC(C)Oc1nc(cc(cc2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnncc2)CC1)=O CXKWGHDNQISAKH-UHFFFAOYSA-N 0.000 description 1
- AQMWFJFVKKPRKB-UHFFFAOYSA-N CC(CC1)CC1N(CC1)CCC1C(N(CC1)CCC1Oc(c(F)cc(F)c1)c1F)=O Chemical compound CC(CC1)CC1N(CC1)CCC1C(N(CC1)CCC1Oc(c(F)cc(F)c1)c1F)=O AQMWFJFVKKPRKB-UHFFFAOYSA-N 0.000 description 1
- FGPASCNFNONGKK-UHFFFAOYSA-N CC(CCC1)C1N(CC1)CCC1C(N(CC1)CCC1Oc(c(F)cc(F)c1)c1F)=O Chemical compound CC(CCC1)C1N(CC1)CCC1C(N(CC1)CCC1Oc(c(F)cc(F)c1)c1F)=O FGPASCNFNONGKK-UHFFFAOYSA-N 0.000 description 1
- PNRIBTZRLWCGCY-LWXMVJRBSA-N CCCC(CCN(CC)CC1=CCNC=C1)C(N(CC1)CCC1N(C/C=C(\C(\Cl)=C/CN)/Cl)C=O)=O Chemical compound CCCC(CCN(CC)CC1=CCNC=C1)C(N(CC1)CCC1N(C/C=C(\C(\Cl)=C/CN)/Cl)C=O)=O PNRIBTZRLWCGCY-LWXMVJRBSA-N 0.000 description 1
- NRBLAGNUDUQVHI-UHFFFAOYSA-N CCCOc1nc(cc(cc2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnncc2)CC1)=O Chemical compound CCCOc1nc(cc(cc2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnncc2)CC1)=O NRBLAGNUDUQVHI-UHFFFAOYSA-N 0.000 description 1
- GLRMTYSXEATZEM-UHFFFAOYSA-N CCCSc1nc2cc(F)ccc2[n]1C(CC1)CCN1C(C1CCN(Cc2ccnnc2)CC1)=O Chemical compound CCCSc1nc2cc(F)ccc2[n]1C(CC1)CCN1C(C1CCN(Cc2ccnnc2)CC1)=O GLRMTYSXEATZEM-UHFFFAOYSA-N 0.000 description 1
- QOORMCGPKZNHRV-UHFFFAOYSA-N CCCc1nc(cc(cc2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2ccnnc2)CC1)=O Chemical compound CCCc1nc(cc(cc2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2ccnnc2)CC1)=O QOORMCGPKZNHRV-UHFFFAOYSA-N 0.000 description 1
- ZMLUYNUBUIEOEG-UHFFFAOYSA-N CCOc1nc(cc(cc2)F)c2[n]1C1CCN(CC2CCN(Cc3cnc(N)nc3)CC2)CC1 Chemical compound CCOc1nc(cc(cc2)F)c2[n]1C1CCN(CC2CCN(Cc3cnc(N)nc3)CC2)CC1 ZMLUYNUBUIEOEG-UHFFFAOYSA-N 0.000 description 1
- BMPKRLDEWOBBNK-UHFFFAOYSA-N CCSc1nc(cc(c(F)c2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnc(N)nc2)CC1)=O Chemical compound CCSc1nc(cc(c(F)c2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnc(N)nc2)CC1)=O BMPKRLDEWOBBNK-UHFFFAOYSA-N 0.000 description 1
- VJZOISUUHDGNFN-UHFFFAOYSA-N CCSc1nc2cccnc2[n]1C(CC1)CCN1C(C1(CCN(Cc2cnc(N)nc2)CC1)F)=O Chemical compound CCSc1nc2cccnc2[n]1C(CC1)CCN1C(C1(CCN(Cc2cnc(N)nc2)CC1)F)=O VJZOISUUHDGNFN-UHFFFAOYSA-N 0.000 description 1
- DABWGTULBIUNJI-UHFFFAOYSA-N CN(C)S(N(CC1)CCN1C(C1CCN(Cc2ccncc2)CC1)=O)(=O)=O Chemical compound CN(C)S(N(CC1)CCN1C(C1CCN(Cc2ccncc2)CC1)=O)(=O)=O DABWGTULBIUNJI-UHFFFAOYSA-N 0.000 description 1
- WGVSVPXDHMZQIG-UHFFFAOYSA-N CN(C)S(c(cc(CN(CC1)CCN1C(C1CCN(Cc2ccnc(N)c2)CC1)=O)c(Cl)c1)c1F)(=O)=O Chemical compound CN(C)S(c(cc(CN(CC1)CCN1C(C1CCN(Cc2ccnc(N)c2)CC1)=O)c(Cl)c1)c1F)(=O)=O WGVSVPXDHMZQIG-UHFFFAOYSA-N 0.000 description 1
- GRXQXRMMQDPVRJ-UHFFFAOYSA-N CN(C)S(c1cc(F)ccc1CN(CC1)CCN1C(C1CCN(Cc2ccnc(N)c2)CC1)=O)(=O)=O Chemical compound CN(C)S(c1cc(F)ccc1CN(CC1)CCN1C(C1CCN(Cc2ccnc(N)c2)CC1)=O)(=O)=O GRXQXRMMQDPVRJ-UHFFFAOYSA-N 0.000 description 1
- YBKAJYQFCUFNHG-UHFFFAOYSA-N CN(C)S(c1cccc(CN(CC2)CCN2C(C2CCN(Cc3ccnc(N)c3)CC2)=O)c1)(=O)=O Chemical compound CN(C)S(c1cccc(CN(CC2)CCN2C(C2CCN(Cc3ccnc(N)c3)CC2)=O)c1)(=O)=O YBKAJYQFCUFNHG-UHFFFAOYSA-N 0.000 description 1
- OELPTECUJYNOBV-UHFFFAOYSA-N CN(C)c1c(cccc2S(N(CC3)CCN3C(C3CCN(Cc4ccncc4)CC3)=O)(=O)=O)c2ccc1 Chemical compound CN(C)c1c(cccc2S(N(CC3)CCN3C(C3CCN(Cc4ccncc4)CC3)=O)(=O)=O)c2ccc1 OELPTECUJYNOBV-UHFFFAOYSA-N 0.000 description 1
- RWTXBQAAGCMMRR-UHFFFAOYSA-N CN1C=C(CN(CC2)CCC2C(N(CC2)CCC2[n]2c(SC)nc(cc3F)c2cc3F)=O)C=NC1N Chemical compound CN1C=C(CN(CC2)CCC2C(N(CC2)CCC2[n]2c(SC)nc(cc3F)c2cc3F)=O)C=NC1N RWTXBQAAGCMMRR-UHFFFAOYSA-N 0.000 description 1
- CYGXTGPAFMRTAW-UHFFFAOYSA-N CNc(cc(c(F)c1)F)c1N(CSC)C(CC1)CCN1C(C1(CCN(Cc2ccnc(N)c2)CC1)F)=O Chemical compound CNc(cc(c(F)c1)F)c1N(CSC)C(CC1)CCN1C(C1(CCN(Cc2ccnc(N)c2)CC1)F)=O CYGXTGPAFMRTAW-UHFFFAOYSA-N 0.000 description 1
- KEYMDDZNWWVYQA-UHFFFAOYSA-N COc1nc(cc(cc2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnncc2)CC1)=O Chemical compound COc1nc(cc(cc2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnncc2)CC1)=O KEYMDDZNWWVYQA-UHFFFAOYSA-N 0.000 description 1
- ZFJQXEJVJRNQDL-UHFFFAOYSA-N CSC1N(C(CC2)CCN2C(C2CCN(Cc3ccnnc3)CC2)=O)c(cc(c(F)c2)F)c2N1 Chemical compound CSC1N(C(CC2)CCN2C(C2CCN(Cc3ccnnc3)CC2)=O)c(cc(c(F)c2)F)c2N1 ZFJQXEJVJRNQDL-UHFFFAOYSA-N 0.000 description 1
- GPPAAXYLDJZLPS-UHFFFAOYSA-N CSc1nc(cc(C(F)(F)F)cc2)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnc(N)nc2)CC1)=O Chemical compound CSc1nc(cc(C(F)(F)F)cc2)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnc(N)nc2)CC1)=O GPPAAXYLDJZLPS-UHFFFAOYSA-N 0.000 description 1
- PFXCGTRUDGQDLW-UHFFFAOYSA-N CSc1nc(cc(C(F)(F)F)cc2)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnncc2)CC1)=O Chemical compound CSc1nc(cc(C(F)(F)F)cc2)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnncc2)CC1)=O PFXCGTRUDGQDLW-UHFFFAOYSA-N 0.000 description 1
- SWYHDWDTOWAXHF-UHFFFAOYSA-N CSc1nc(cc(c(F)c2)F)c2[n]1C(CC1)CCN1C(C1(CCN(Cc2ccncc2)CC1)F)=O Chemical compound CSc1nc(cc(c(F)c2)F)c2[n]1C(CC1)CCN1C(C1(CCN(Cc2ccncc2)CC1)F)=O SWYHDWDTOWAXHF-UHFFFAOYSA-N 0.000 description 1
- FPNSGKWODIUIAL-UHFFFAOYSA-N CSc1nc(cc(c(F)c2)F)c2[n]1C(CC1)CCN1C(C1(CCN(Cc2cnncc2)CC1)F)=O Chemical compound CSc1nc(cc(c(F)c2)F)c2[n]1C(CC1)CCN1C(C1(CCN(Cc2cnncc2)CC1)F)=O FPNSGKWODIUIAL-UHFFFAOYSA-N 0.000 description 1
- MPRZHWCJTHKLFI-UHFFFAOYSA-N CSc1nc(cc(c(F)c2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2ccnc(N)c2)CC1)=O Chemical compound CSc1nc(cc(c(F)c2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2ccnc(N)c2)CC1)=O MPRZHWCJTHKLFI-UHFFFAOYSA-N 0.000 description 1
- HHGOKMZLJCUXJY-UHFFFAOYSA-N CSc1nc(cc(c(F)c2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2ccncc2)CC1)=O Chemical compound CSc1nc(cc(c(F)c2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2ccncc2)CC1)=O HHGOKMZLJCUXJY-UHFFFAOYSA-N 0.000 description 1
- LBZGDPGUILJAET-UHFFFAOYSA-N CSc1nc(cc(cc2)Cl)c2[n]1C(CC1)CCN1C(C1(CCN(Cc2cnc(N)nc2)CC1)F)=O Chemical compound CSc1nc(cc(cc2)Cl)c2[n]1C(CC1)CCN1C(C1(CCN(Cc2cnc(N)nc2)CC1)F)=O LBZGDPGUILJAET-UHFFFAOYSA-N 0.000 description 1
- KTKLCWROEACXIR-UHFFFAOYSA-N CSc1nc(cc(cc2)Cl)c2[n]1C(CC1)CCN1C(C1(CCN(Cc2cnncc2)CC1)F)=O Chemical compound CSc1nc(cc(cc2)Cl)c2[n]1C(CC1)CCN1C(C1(CCN(Cc2cnncc2)CC1)F)=O KTKLCWROEACXIR-UHFFFAOYSA-N 0.000 description 1
- JAAITEZSYVRBMB-UHFFFAOYSA-N CSc1nc(cc(cc2)F)c2[n]1C1CCN(CC2CCN(CC3=CCNN=C3)CC2)CC1 Chemical compound CSc1nc(cc(cc2)F)c2[n]1C1CCN(CC2CCN(CC3=CCNN=C3)CC2)CC1 JAAITEZSYVRBMB-UHFFFAOYSA-N 0.000 description 1
- VRALHKKCZZEKBO-UHFFFAOYSA-N CSc1nc(cc(cc2)S(=O)=O)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnc(N)nc2)CC1)=O Chemical compound CSc1nc(cc(cc2)S(=O)=O)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnc(N)nc2)CC1)=O VRALHKKCZZEKBO-UHFFFAOYSA-N 0.000 description 1
- FRIQUYNEPHSNFB-UHFFFAOYSA-N CSc1nc2cc(F)ccc2[n]1C1CCN(CC2CCN(Cc3cnc(N)nc3)CC2)CC1 Chemical compound CSc1nc2cc(F)ccc2[n]1C1CCN(CC2CCN(Cc3cnc(N)nc3)CC2)CC1 FRIQUYNEPHSNFB-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- TXZRZYQPAMLXLP-UHFFFAOYSA-N Cc1c2nc(-c3ncccc3)[n](C(CC3)CCN3C(C3CCN(Cc4ccnc(N)c4)CC3)=O)c2ccc1 Chemical compound Cc1c2nc(-c3ncccc3)[n](C(CC3)CCN3C(C3CCN(Cc4ccnc(N)c4)CC3)=O)c2ccc1 TXZRZYQPAMLXLP-UHFFFAOYSA-N 0.000 description 1
- BXGFHAAJUAOMBY-UHFFFAOYSA-N Cc1c2nc(-c3ncccc3)[n](C(CC3)CCN3C(C3CCN(Cc4ccnnc4)CC3)=O)c2ccc1 Chemical compound Cc1c2nc(-c3ncccc3)[n](C(CC3)CCN3C(C3CCN(Cc4ccnnc4)CC3)=O)c2ccc1 BXGFHAAJUAOMBY-UHFFFAOYSA-N 0.000 description 1
- HUTBMBHYCVUWGW-UHFFFAOYSA-N Cc1c2nc(-c3ncccc3)[n](C(CC3)CCN3C(C3CCN(Cc4cnc(N)nc4)CC3)=O)c2ccc1 Chemical compound Cc1c2nc(-c3ncccc3)[n](C(CC3)CCN3C(C3CCN(Cc4cnc(N)nc4)CC3)=O)c2ccc1 HUTBMBHYCVUWGW-UHFFFAOYSA-N 0.000 description 1
- OUKSTAPGLALCBV-UHFFFAOYSA-N Cc1n[o]c(C)c1CN(CC1)CCN1C(C1CCN(Cc2ccnc(N)c2)CC1)=O Chemical compound Cc1n[o]c(C)c1CN(CC1)CCN1C(C1CCN(Cc2ccnc(N)c2)CC1)=O OUKSTAPGLALCBV-UHFFFAOYSA-N 0.000 description 1
- VVZSANCFQKOOEH-UHFFFAOYSA-N Cc1nc(cc(cc2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnc(N)nc2)CC1)=O Chemical compound Cc1nc(cc(cc2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnc(N)nc2)CC1)=O VVZSANCFQKOOEH-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- URRAHSMDPCMOTH-LNLFQRSKSA-N Denagliptin Chemical compound C=1C=C(F)C=CC=1C([C@H](N)C(=O)N1[C@@H](C[C@H](F)C1)C#N)C1=CC=C(F)C=C1 URRAHSMDPCMOTH-LNLFQRSKSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 description 1
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 125000005850 N-(alkoxycarbonyl)aminomethyl group Chemical group 0.000 description 1
- PHMXEKLFRTUXTP-CLAGLONPSA-N N=C/C=C\C(CN(CC1)CCC1(C(N(CC1)CCC1[n](c(-c1ncccc1)c1)c2c1cccc2)=O)F)=N Chemical compound N=C/C=C\C(CN(CC1)CCC1(C(N(CC1)CCC1[n](c(-c1ncccc1)c1)c2c1cccc2)=O)F)=N PHMXEKLFRTUXTP-CLAGLONPSA-N 0.000 description 1
- ZEXNSLQCRURDFB-UHFFFAOYSA-N Nc(cccc1)c1C(NC1C2=CC=CC1)=C2C(CC1)=CCN1C(C1(CCN(Cc2cnc(N)nc2)CC1)F)=O Chemical compound Nc(cccc1)c1C(NC1C2=CC=CC1)=C2C(CC1)=CCN1C(C1(CCN(Cc2cnc(N)nc2)CC1)F)=O ZEXNSLQCRURDFB-UHFFFAOYSA-N 0.000 description 1
- DLXSNFRYPHDVOA-UHFFFAOYSA-N Nc1c(CN(CC2)CCC2C(N(CC2)CCC2[n]2c3ccccc3cc2-c2ncccc2)=O)ccnc1 Chemical compound Nc1c(CN(CC2)CCC2C(N(CC2)CCC2[n]2c3ccccc3cc2-c2ncccc2)=O)ccnc1 DLXSNFRYPHDVOA-UHFFFAOYSA-N 0.000 description 1
- BINJSFASDUWRDA-UHFFFAOYSA-N Nc1cc(CN(CC2)CCC2(C(N(CC2)CCC2[n]2c(-c3ccccn3)nc3cccnc23)=O)F)ccn1 Chemical compound Nc1cc(CN(CC2)CCC2(C(N(CC2)CCC2[n]2c(-c3ccccn3)nc3cccnc23)=O)F)ccn1 BINJSFASDUWRDA-UHFFFAOYSA-N 0.000 description 1
- PGUHJCXJZOUUBX-UHFFFAOYSA-N Nc1cc(CN(CC2)CCC2C(N2CCN(CC(C(F)=CC3)=CC3Br)CC2)=O)ccn1 Chemical compound Nc1cc(CN(CC2)CCC2C(N2CCN(CC(C(F)=CC3)=CC3Br)CC2)=O)ccn1 PGUHJCXJZOUUBX-UHFFFAOYSA-N 0.000 description 1
- OUPLNHQJQQLVIV-UHFFFAOYSA-N Nc1cc(CN(CC2)CCC2C(N2CCN(CC(Nc3ccccn3)=O)CC2)=O)ccn1 Chemical compound Nc1cc(CN(CC2)CCC2C(N2CCN(CC(Nc3ccccn3)=O)CC2)=O)ccn1 OUPLNHQJQQLVIV-UHFFFAOYSA-N 0.000 description 1
- VQOOWSGZHDNPSZ-UHFFFAOYSA-N Nc1cc(CN(CC2)CCC2C(N2CCN(Cc3cc(Cl)ccc3F)CC2)=O)ccn1 Chemical compound Nc1cc(CN(CC2)CCC2C(N2CCN(Cc3cc(Cl)ccc3F)CC2)=O)ccn1 VQOOWSGZHDNPSZ-UHFFFAOYSA-N 0.000 description 1
- FIMDFLQFQJDZCY-UHFFFAOYSA-N Nc1cc(CN(CC2)CCC2C(N2CCN(Cc3ccccc3S(N3CCCC3)(=O)=O)CC2)=O)ccn1 Chemical compound Nc1cc(CN(CC2)CCC2C(N2CCN(Cc3ccccc3S(N3CCCC3)(=O)=O)CC2)=O)ccn1 FIMDFLQFQJDZCY-UHFFFAOYSA-N 0.000 description 1
- VULGOVVHQWHTPF-UHFFFAOYSA-N Nc1cc(CN(CC2)CCC2C(N2CCN(Cc3ncccc3)CC2)=O)ccn1 Chemical compound Nc1cc(CN(CC2)CCC2C(N2CCN(Cc3ncccc3)CC2)=O)ccn1 VULGOVVHQWHTPF-UHFFFAOYSA-N 0.000 description 1
- QILCEWIESORCHV-UHFFFAOYSA-N Nc1ncc(CN(CC2)CCC2(C(N(CC2)CCC2[n]2c(ccc(Br)c3)c3nc2C2N=CC=CC2)=O)F)cn1 Chemical compound Nc1ncc(CN(CC2)CCC2(C(N(CC2)CCC2[n]2c(ccc(Br)c3)c3nc2C2N=CC=CC2)=O)F)cn1 QILCEWIESORCHV-UHFFFAOYSA-N 0.000 description 1
- BOXITBBFGICOLQ-UHFFFAOYSA-N Nc1ncc(CN(CC2)CCC2C(N(CC2)CCC2c2c(-c3ccccn3)[n](CCN3CCCCC3)c3c2cccc3)=O)cn1 Chemical compound Nc1ncc(CN(CC2)CCC2C(N(CC2)CCC2c2c(-c3ccccn3)[n](CCN3CCCCC3)c3c2cccc3)=O)cn1 BOXITBBFGICOLQ-UHFFFAOYSA-N 0.000 description 1
- ADXNRUOPSTYVCY-UHFFFAOYSA-N Nc1nccc(CN(CC2)CCC2C(N(CC2)CCC2c2c(-c3ccccn3)[nH]c3c2cccc3)=O)c1 Chemical compound Nc1nccc(CN(CC2)CCC2C(N(CC2)CCC2c2c(-c3ccccn3)[nH]c3c2cccc3)=O)c1 ADXNRUOPSTYVCY-UHFFFAOYSA-N 0.000 description 1
- VZDMNDHJAAWNLA-UHFFFAOYSA-N Nc1nccc(CN(CC2)CCC2C(N(CC2)CCC2c2c(-c3ncccc3)[n](CCN3CCCCC3)c3c2cccc3)=O)c1 Chemical compound Nc1nccc(CN(CC2)CCC2C(N(CC2)CCC2c2c(-c3ncccc3)[n](CCN3CCCCC3)c3c2cccc3)=O)c1 VZDMNDHJAAWNLA-UHFFFAOYSA-N 0.000 description 1
- CFMNJQFRIJAKBR-UHFFFAOYSA-N Nc1nccc(CN(CC2)CCC2C2OC2N(CC2)CCC2c2c(-c3ccccn3)[nH]c3c2ccc(F)c3)c1 Chemical compound Nc1nccc(CN(CC2)CCC2C2OC2N(CC2)CCC2c2c(-c3ccccn3)[nH]c3c2ccc(F)c3)c1 CFMNJQFRIJAKBR-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- AWOUTVPZOSWMEM-IZZDOVSWSA-N O=C(C(CC1)CCN1/C=C/c1ccccc1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F Chemical compound O=C(C(CC1)CCN1/C=C/c1ccccc1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F AWOUTVPZOSWMEM-IZZDOVSWSA-N 0.000 description 1
- UGYKEPSUIWMLBI-RMQYNXQMSA-N O=C(C(CC1)CCN1C1C(CC2)C[C@@H]2C1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F Chemical compound O=C(C(CC1)CCN1C1C(CC2)C[C@@H]2C1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F UGYKEPSUIWMLBI-RMQYNXQMSA-N 0.000 description 1
- RMKLWOWGQVXOBN-UHFFFAOYSA-N O=C(C(CC1)CCN1C1CCC1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F Chemical compound O=C(C(CC1)CCN1C1CCC1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F RMKLWOWGQVXOBN-UHFFFAOYSA-N 0.000 description 1
- UDYBYMHHRKWEFE-UHFFFAOYSA-N O=C(C(CC1)CCN1C1CCCC1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F Chemical compound O=C(C(CC1)CCN1C1CCCC1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F UDYBYMHHRKWEFE-UHFFFAOYSA-N 0.000 description 1
- ONRSRDUPVPYQQO-UHFFFAOYSA-N O=C(C(CC1)CCN1C1CCCCC1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F Chemical compound O=C(C(CC1)CCN1C1CCCCC1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F ONRSRDUPVPYQQO-UHFFFAOYSA-N 0.000 description 1
- BKGRJZQPEJIGST-UHFFFAOYSA-N O=C(C(CC1)CCN1C1CCOCC1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F Chemical compound O=C(C(CC1)CCN1C1CCOCC1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F BKGRJZQPEJIGST-UHFFFAOYSA-N 0.000 description 1
- OXOAVWIPTGNDDV-UHFFFAOYSA-N O=C(C(CC1)CCN1C1CSCC1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F Chemical compound O=C(C(CC1)CCN1C1CSCC1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F OXOAVWIPTGNDDV-UHFFFAOYSA-N 0.000 description 1
- NNVIDJVXWOFUBP-UHFFFAOYSA-N O=C(C1(CCN(Cc2ccnnc2)CC1)F)N(CC1)CCC1[n](c(-c1ncccc1)c1)c(cc2)c1cc2F Chemical compound O=C(C1(CCN(Cc2ccnnc2)CC1)F)N(CC1)CCC1[n](c(-c1ncccc1)c1)c(cc2)c1cc2F NNVIDJVXWOFUBP-UHFFFAOYSA-N 0.000 description 1
- NZDGHZHVJQTPEV-UHFFFAOYSA-N O=C(C1(CCN(Cc2ccnnc2)CC1)F)N(CC1)CCC1[n]1c(nccc2)c2nc1 Chemical compound O=C(C1(CCN(Cc2ccnnc2)CC1)F)N(CC1)CCC1[n]1c(nccc2)c2nc1 NZDGHZHVJQTPEV-UHFFFAOYSA-N 0.000 description 1
- XXMADFCNRFJJDY-UHFFFAOYSA-N O=C(C1CCN(CC2CCNCC2)CC1)N(CC1)CCC1[n]1c(-c2ncccc2)nc2cc(F)ccc12 Chemical compound O=C(C1CCN(CC2CCNCC2)CC1)N(CC1)CCC1[n]1c(-c2ncccc2)nc2cc(F)ccc12 XXMADFCNRFJJDY-UHFFFAOYSA-N 0.000 description 1
- RTZPHCLGJNXIIZ-UHFFFAOYSA-N O=C(C1CCN(Cc(cc2)ccc2Cl)CC1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F Chemical compound O=C(C1CCN(Cc(cc2)ccc2Cl)CC1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F RTZPHCLGJNXIIZ-UHFFFAOYSA-N 0.000 description 1
- UZHUABFUBCLNMJ-UHFFFAOYSA-N O=C(C1CCN(Cc2c[s]cc2)CC1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F Chemical compound O=C(C1CCN(Cc2c[s]cc2)CC1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F UZHUABFUBCLNMJ-UHFFFAOYSA-N 0.000 description 1
- CUBMUDZQWHYGPO-UHFFFAOYSA-N O=C(C1CCN(Cc2ccc[s]2)CC1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F Chemical compound O=C(C1CCN(Cc2ccc[s]2)CC1)N(CC1)CCC1Oc(c(F)cc(F)c1)c1F CUBMUDZQWHYGPO-UHFFFAOYSA-N 0.000 description 1
- GDZMJNKRHQHZBR-UHFFFAOYSA-N O=C(C1CCN(Cc2cccc(F)c2)CC1)N(CC1)CCC1Oc(c(F)cc([F]c1cc(F)c(CN(CC2)CCC2C(N(CC2)CCC2Oc(c(F)cc(F)c2)c2F)=O)cc1)c1)c1F Chemical compound O=C(C1CCN(Cc2cccc(F)c2)CC1)N(CC1)CCC1Oc(c(F)cc([F]c1cc(F)c(CN(CC2)CCC2C(N(CC2)CCC2Oc(c(F)cc(F)c2)c2F)=O)cc1)c1)c1F GDZMJNKRHQHZBR-UHFFFAOYSA-N 0.000 description 1
- OKHRBGQWDQXLSC-UHFFFAOYSA-N O=C(C1CCN(Cc2cccnn2)CC1)N(CC1)CCC1[n]1c2ccccc2cc1-c1ncccc1 Chemical compound O=C(C1CCN(Cc2cccnn2)CC1)N(CC1)CCC1[n]1c2ccccc2cc1-c1ncccc1 OKHRBGQWDQXLSC-UHFFFAOYSA-N 0.000 description 1
- HUPSFFIBHGIFKH-UHFFFAOYSA-N O=C(C1CCN(Cc2ccncc2)CC1)N(CC1)CCN1S(c(cc1)ccc1Cl)(=O)=O Chemical compound O=C(C1CCN(Cc2ccncc2)CC1)N(CC1)CCN1S(c(cc1)ccc1Cl)(=O)=O HUPSFFIBHGIFKH-UHFFFAOYSA-N 0.000 description 1
- JVEXNOGSYXTUKF-UHFFFAOYSA-N O=C(C1CCN(Cc2ccncc2)CC1)N(CC1)CCN1S(c1cccc2c1nccc2)(=O)=O Chemical compound O=C(C1CCN(Cc2ccncc2)CC1)N(CC1)CCN1S(c1cccc2c1nccc2)(=O)=O JVEXNOGSYXTUKF-UHFFFAOYSA-N 0.000 description 1
- QLKGHIPHGABLCR-UHFFFAOYSA-N O=C(C1CCN(Cc2ccncc2)CC1)N(CC1)CCN1S(c1cccc2cnccc12)(=O)=O Chemical compound O=C(C1CCN(Cc2ccncc2)CC1)N(CC1)CCN1S(c1cccc2cnccc12)(=O)=O QLKGHIPHGABLCR-UHFFFAOYSA-N 0.000 description 1
- NRQRHAZEZKQKQH-UHFFFAOYSA-N O=C(C1CCN(Cc2ccncc2)CC1)N(CC1)CCN1S(c1ccccc1)(=O)=O Chemical compound O=C(C1CCN(Cc2ccncc2)CC1)N(CC1)CCN1S(c1ccccc1)(=O)=O NRQRHAZEZKQKQH-UHFFFAOYSA-N 0.000 description 1
- KXCGISHLTHZKNP-UHFFFAOYSA-N O=C(C1CCN(Cc2ccncc2)CC1)N1CCN(Cc(c(S(N2CCOCC2)(=O)=O)ccc2)c2Cl)CC1 Chemical compound O=C(C1CCN(Cc2ccncc2)CC1)N1CCN(Cc(c(S(N2CCOCC2)(=O)=O)ccc2)c2Cl)CC1 KXCGISHLTHZKNP-UHFFFAOYSA-N 0.000 description 1
- XBPGUCODJJXJNQ-UHFFFAOYSA-N O=C(C1CCN(Cc2ccnnc2)CC1)N(CC1)CCC1N1C(c2ncccc2)=CC2C1=CC=CC2 Chemical compound O=C(C1CCN(Cc2ccnnc2)CC1)N(CC1)CCC1N1C(c2ncccc2)=CC2C1=CC=CC2 XBPGUCODJJXJNQ-UHFFFAOYSA-N 0.000 description 1
- DKIBFLPZOSEUAQ-UHFFFAOYSA-N O=C(C1CCN(Cc2ccnnc2)CC1)N(CC1)CCC1[n]1c(-c2ncccc2)nc2c1ccc(Cl)c2 Chemical compound O=C(C1CCN(Cc2ccnnc2)CC1)N(CC1)CCC1[n]1c(-c2ncccc2)nc2c1ccc(Cl)c2 DKIBFLPZOSEUAQ-UHFFFAOYSA-N 0.000 description 1
- RDVIABHSNRCRJX-UHFFFAOYSA-N Oc1ccc(CN(CC2)CCC2C(N(CC2)CCC2Oc(c(F)cc(F)c2)c2F)=O)cc1 Chemical compound Oc1ccc(CN(CC2)CCC2C(N(CC2)CCC2Oc(c(F)cc(F)c2)c2F)=O)cc1 RDVIABHSNRCRJX-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229950000562 amlintide Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000001708 anti-dyslipidemic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- BDIIXJCOXLQTKD-UHFFFAOYSA-N azetidin-1-amine Chemical compound NN1CCC1 BDIIXJCOXLQTKD-UHFFFAOYSA-N 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005513 benzoazaindolyl group Chemical group 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 150000005347 biaryls Chemical class 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229950001261 camiglibose Drugs 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940066901 crestor Drugs 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950010300 denagliptin Drugs 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical class CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 229950002375 englitazone Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000005643 gamma-butyrolacton-4-yl group Chemical group 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229950004153 gliamilide Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229940095884 glucophage Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 150000002373 hemiacetals Chemical group 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000005367 heteroarylalkylthio group Chemical group 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 125000005368 heteroarylthio group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 229940095570 lescol Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229940099246 mevacor Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000005858 morpholino(C2-C3)alkyl group Chemical group 0.000 description 1
- MQQJZPWSYVPWPF-QYZOEREBSA-N n-[2-[1-[[(1r,4r,5r)-5-bicyclo[2.2.1]hept-2-enyl]methylcarbamoylsulfamoyl]piperidin-4-yl]ethyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=CC=C1C(=O)NCCC1CCN(S(=O)(=O)NC(=O)NC[C@H]2[C@@H]3C[C@@H](C=C3)C2)CC1 MQQJZPWSYVPWPF-QYZOEREBSA-N 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003227 neuromodulating effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- BNYHRGTXRPWASY-UHFFFAOYSA-N nonylsulfonylurea Chemical compound CCCCCCCCCS(=O)(=O)NC(N)=O BNYHRGTXRPWASY-UHFFFAOYSA-N 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 150000003901 oxalic acid esters Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 125000005856 piperidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- TZIRZGBAFTZREM-MKAGXXMWSA-N pramlintide Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 TZIRZGBAFTZREM-MKAGXXMWSA-N 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- 229940089484 pravachol Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000005857 pyrrolidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960004796 rosuvastatin calcium Drugs 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- PHWXUGHIIBDVKD-UHFFFAOYSA-N sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 description 1
- 229960002578 sitaxentan Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 1
- 229960002909 spirapril Drugs 0.000 description 1
- 108700035424 spirapril Proteins 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
- 125000005853 β-dimethylaminoethyl group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Definitions
- the present invention relates to pharmaceutical compositions comprising therapeutic combinations comprising: one or more H 3 antagonists/inverse agonists; one or more appetite suppressants selected from the group consisting of CBi antagonists/inverse agonists, sibutramine, phentermine and topiramate; and optionally one or more HMG-CoA reductase inhibitors.
- the invention also relates to medicaments and kits comprising the pharmaceutical compositions of the present invention, and methods of treating obesity, obesity related disorders and diabetes using the pharmaceutical compositions of the present invention.
- H 1 , H 2 , H3 and H* have been characterized by their pharmacological behavior.
- the H 1 receptors are those that mediate the response antagonized by conventional antihistamines.
- H 1 receptors are present, for example, in the ileum, the skin, and the bronchial smooth muscle of humans and other mammals.
- the most prominent H 2 receptor-mediated responses are the secretion of gastric acid in mammals and the chronotropic effect in isolated mammalian atria.
- H 4 receptors are expressed primarily on eosinophils and mast cells and have been shown to be involved in the chemotaxis of both cell types.
- H 3 receptor sites are found on sympathetic nerves, where they modulate sympathetic neurotransmission and attenuate a variety of end organ responses under control of the sympathetic nervous system. Specifically, H 3 receptor activation by histamine attenuates norepinephrine outflow to resistance and capacitance vessels, causing vasodilation. In addition, in rodents, peripheral H3 receptors are expressed in brown adipose tissue, suggesting that they may be involved in thermogenesis regulation.
- H 3 receptors are also present in the CNS. H 3 receptor expression is observed in cerebral cortex, hippocampal formation, hypothalamus and other parts of the human and animal brain. H 3 receptors are expressed on histaminergic neurons where they function as autoreceptors and, on neurons involved in other neurotransmitter systems, where they function as heteroreceptors. In both cases H 3 receptor activation results in presynaptic inhibition of neurotransmitter release. In the particular case, of histaminergic neurons, H 3 receptors have been implicated in the regulation of hypothalamic histamine tone, which in turn has been associated with the modulation of sleeping, feeding and cognitive processes in the human brain (see, for example, Leurs et al., Nature Reviews, Drug Discovery, 4, (2005), 107).
- H 3 receptor antagonists may be useful in treating various neuropsychiatric conditions, where cognitive deficits are an integral part of the disease, specifically ADHD, schizophrenia and Alzheimer's disease.
- Imidazole H 3 receptor antagonists are well known in the art. More recently, non-imidazole H 3 receptor antagonists have been disclosed in US Patents 6,720,328 and 6 7 849,621 , and in US Published Applications 2004/0097483, 2004/0048843 and 2004/0019099.
- WO 95/14007 discloses H3 receptor antagonists of the imidazole type.
- WO 99/24405 discloses H 3 receptor ligands of the imidazole type.
- US 5,869,479 discloses compositions for the treatment of the symptoms of allergic rhinitis using a combination of at least one histamine Hi receptor antagonist and at least one histamine H 3 receptor antagonist.
- HMG-CoA reductase inhibitors e.g., statins such as lovastatin, simvastatin, pravastatin, atorvastatin, fluvastatin, and resuvastatin, slow the progression of atherosclerotic lesions in the coronary and carotid arteries.
- statins such as lovastatin, simvastatin, pravastatin, atorvastatin, fluvastatin, and resuvastatin
- Simvastatin, atorvastatin and pravastatin have also been shown to reduce the risk of coronary heart disease events in patients with hypercholesterolemia and/or atherosclerotic coronary heart disease (CHD).
- Simvastatin is marketed worldwide, and sold in the U.S. under the tradename
- the CBi receptor is one of the most abundant neuromodulatory receptors in the brain, and is expressed at high levels in the hippocampus, cortex, cerebellum, and basal ganglia (e.g., Wilson et al., Science, 2002, vol. 296, 678-682).
- Selective CBi receptor antagonists for example pyrazole derivatives such as rimonabant, can be used to treat various conditions, such as obesity and metabolic syndrome (e.g., Bensaid et al., Molecular Pharmacology, 2003 vol. 63, no. 4, pp. 908-914; Trillou et al., Am. J. Physiol. Regul. Inlegr. Comp. Physiol. 2002 vol. 284, R345-R353; Kirkham, Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002 vol. 284, R343-R344; Sanof ⁇ -
- CBi receptor antagonists e.g., rimonabant
- HDL-C serum high density lipoprotein cholesterol
- Sibutramine has been shown to reduce food intake (e.g., Halford et al., British Journal of Pharmacology 1994, 114: Proc Suppl (387P); Stricker-Krongrad et al., International Journal of Obesity 1995, 19: Suppl 2 (145)) and increase oxygen consumption and body core temperature (Connoley et al., British Journal of Pharmacology 1994, 114:Proc Suppl (388P)).
- Phentermine is an appetite suppressant used for treating obesity (e.g., D. Craddock, Drugs 1976; 11 :378).
- WO 2004/110368 describes combination therapies for the treatment of hypertension comprising the combination of an anti-obesity agent and an anti- hypertensive agent.
- WO 2005/000217 describes combination therapies for the treatment of dyslipidemia comprising the administration of a combination of an anti-obesity agent and an anti-dyslipidemic agent.
- WO 2004/110375 describes combination therapies for the treatment of diabetes comprising the administration of a combination of an anti-obesity agent and an anti-diabetic agent.
- US 2004/0122033 describes combination therapies for the treatment of obesity comprising the administration of a combination of an appetite suppressant and/or metabolic rate enhancers and/or nutrient absorption inhibitors.
- US 2004/0229844 describes combination therapies for treating atherosclerosis comprising the administration of a combination of nicotinic acid or another nicotinic acid receptor agonist and a DP receptor antagonist.
- an H 3 antagonist/inverse agonist with an appetite suppressant selected from the group consisting of a CEh antagonist (e.g., rimonabant), sibutramine, phentermine and topiramate
- a CEh antagonist e.g., rimonabant
- sibutramine e.g., sibutramine
- phentermine e.g., phentermine
- U.S. 6,437,147, 6,756,384, and 2003/0135056 describe combinations of imidazo heterocyclic compounds which bind to the H 3 receptor with antiobesity agents or appetite regulating agents, including sibutramine, phentermine, topiramate, lovastatin, pravastatin, and simvastatin.
- antiobesity agents or appetite regulating agents including sibutramine, phentermine, topiramate, lovastatin, pravastatin, and simvastatin.
- the compounds of U.S. 6,437,147, 6,756,384, and 2003/0135056 which bind to the H 3 receptor are different from the H 3 antagonists/inverse agonists of Formulae (I)-(VI) of the present invention.
- 6,673,829 and 2003/0130253 describe combinations of aminoazetidine, pyrrolidine, and piperidine derivatives which bind to the H 3 receptor with antiobesity agents or appetite regulating agents, including sibutramine, phentermine, topiramate, lovastatin, pravastatin, and simvastatin.
- antiobesity agents or appetite regulating agents including sibutramine, phentermine, topiramate, lovastatin, pravastatin, and simvastatin.
- the compounds of U.S. 6,673,829 and 2003/0130253 which bind to the H 3 receptor are different from the H 3 antagonists/inverse agonists of Formulae (I)-(VI) of the present invention.
- U.S. 6,417,218 and 2002/0058659 describe combinations of imidazole compounds which bind to the H 3 receptor with antiobesity agents or appetite regulating agents, including sibutramine, phentermine, topiramate, lovastatin, pravastatin, and simvastatin.
- antiobesity agents or appetite regulating agents including sibutramine, phentermine, topiramate, lovastatin, pravastatin, and simvastatin.
- the compounds of U.S. 6,417,218 and 2002/0058659 which bind to the H 3 receptor are different from the H 3 antagonists/inverse agonists of Formulae (I)-(VI) of the present invention.
- U.S. 2004/0248938 and 2003/0186963 describe combinations of substituted piperidines which bind to the H 3 receptor with antiobesity agents or appetite regulating agents, including sibutramine, phentermine, topiramate, lovastatin, pravastatin, and simvastatin.
- antiobesity agents or appetite regulating agents including sibutramine, phentermine, topiramate, lovastatin, pravastatin, and simvastatin.
- the compounds of U.S. 2004/0248938 and 2003/0186963 which bind to the H 3 receptor are different from the H 3 antagonists/inverse agonists of Formulae (I)-(VI) of the present invention.
- the present invention is directed to a composition
- a composition comprising one or more appetite suppressants selected from the group consisting of CBi antagonists/inverse agonists (e.g., rimonabant), sibutramine, phentermine, and topiramate, in combination with one or more metabolic rate enhancers comprising an H 3 antagonist/inverse agonist of Formula (I)-(VIII) (as defined herein).
- the present invention is directed to a pharmaceutical composition
- a pharmaceutical composition comprising one or more appetite suppressants selected from the group consisting of CBi antagonists/inverse agonists (e.g., rimonabant), sibutramine, phentermine, and topiramate, in combination with one or more metabolic rate enhancers comprising an H 3 antagonist/inverse agonist of Formula (I)-(VIiI) (as defined herein), and at least one pharmaceutically acceptable carrier.
- the present invention is directed to a pharmaceutical u ; ⁇ ., ⁇ m ⁇ neinn nno nr moro annptitp si jnnressants selected from the ⁇ rouD consisting of CBi antagonists/inverse agonists (e.g., rimonabant), sibutramine, phentermine, and topiramate, in combination with one or more metabolic rate enhancers comprising an H 3 antagonist/inverse agonist, and one or more HMG-CoA reductase inhibitors.
- the present invention is directed to a method of treating obesity or an obesity-related disorder.
- the method comprises administering to the patient an effective amount of a composition comprising one or more appetite suppressants selected from the group consisting of CBi antagonists/inverse agonjsts (e.g., rimonabant), sibutramine, phentermine, and topiramate, in combination with one or more metabolic rate enhancers comprising an H 3 antagonist/inverse agonist of Formula (I)-(VIII) (as defined herein).
- a composition comprising one or more appetite suppressants selected from the group consisting of CBi antagonists/inverse agonjsts (e.g., rimonabant), sibutramine, phentermine, and topiramate, in combination with one or more metabolic rate enhancers comprising an H 3 antagonist/inverse agonist of Formula (I)-(VIII) (as defined herein).
- the present invention is directed to a method of treating obesity or an obesity-related disorder.
- the method comprises administering to the patient an effective amount of one or more appetite suppressants selected from the group consisting of CBi antagonists/inverse agonists (e.g., rimonabant), sibutramine, phentermine, and topiramate, in combination with one or more metabolic rate enhancers comprising an H 3 antagonist/inverse, and one or more HMG-CoA reductase inhibitors.
- a "patient” is a human or non-human mammal.
- a patient is a human.
- a patient is a non-human mammal, including, but not limited to, a monkey, dog, baboon, rhesus, mouse, rat, horse, cat or rabbit.
- a patient is a companion animal, including but not limited to a dog, cat, rabbit, horse or ferret.
- a patient is a dog.
- a patient is a cat.
- Alkyl means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain.
- the alkyl groups can contain about 1 to about 12 carbon atoms in the chain, and in another embodiment, the alkyl groups can contain about 1 to about 6 carbon atoms in the chain.
- Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain.
- “Lower alkyl” means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched.
- substituted alkyl means that the alkyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl) 2 , carboxy and -C(O)O-alkyl.
- suitable alkyl groups include methyl, ethyl, n- propyl, isopropyl and t-butyl.
- Alkylene means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above.
- alkylene include methylene (i.e., -CH 2 -), ethylene (i.e., -CH 2 CH 2 - or -CH(CH 3 )-), propylene (i.e., -CH 2 CH 2 CH 2 -, -CH 2 CH(CH 3 )-, -CH(CH 3 )CH 2 -, Or -CH(CH 2 CH 3 )-), butylene (i.e., -CH 2 CH 2 CH 2 CH 2 -, -CH 2 CH 2 CH(CH 3 )-, -CH 2 CH(CH 3 )CH 2 - ⁇ CH(CH 2 CH 2 CH 3 )-, etc.).
- “Lower alkylene” means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched.
- Alkenyl means a hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Alkenyl groups can have about 2 to about 12 carbon atoms in the chain; and in another embodiment, about 2 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain. "Lower alkenyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched.
- substituted alkenyl means that the alkenyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, alkoxy, and -S(alkyt).
- suitable alkenyl groups include ethenyl, propenyl (i.e., allyl), n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl and decenyl.
- Alkenylene means a difunctional group obtained by removal of a hydrogen from an alkenyl group that is defined above.
- Alkynyl means a hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Alkynyl groups can have about 2 to about 12 carbon atoms in the chain, and in another embodiment, about 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain. "Lower alkynyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched.
- Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbuty ⁇ yl.
- substituted alkynyl means that the alkynyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, aryl and cycloalkyl.
- Alkynylene means a difunctional group obtained by removal of a hydrogen from an alkynyl group that is defined above.
- Aryl means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, an in another embodiment, about 6 to about 10 carbon atoms.
- the aryl group can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein.
- suitable aryl groups include phenyl and naphthyl.
- Heteroaryl means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, and in another embodiment, about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination.
- Heteroaryls can contain about 5 to about 6 ring atoms.
- the "heteroaryl” can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein.
- the prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom.
- a nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide.
- Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1 ,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1 ,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyrid
- heteroaryl also refers to partially saturated heteroaryl moieties such as, for example, tetrahydroisoquinolyl, tetrahydroqu ⁇ nolyl, indazolyl, and the like, in which there is at least one aromatic ring.
- Alkylene-aryl (or aryl-alkylene-) means a group in which the aryl and alkylene are as previously described. The bond to the parent moiety is through the alkylene. The alkylene moiety can be bonded to one or more aryl moieties. Alkylene-aryls can comprise a lower alkylene group. Non-timiting examples of suitable alkylene-aryl groups include benzyl, 2-phenethyl, 2,2-d ⁇ phenylethylene and naphthaienylmethyl.
- Alkylaryl means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Alkylaryls can comprise a lower alkyl group. Non-limiting examples of suitable alkylaryl groups include tolyl and xylyl. The bond to the parent moiety is through the aryl.
- Alkylheteroaryl means an alkyl-heteroaryl- group in which the alkyl and heteroaryl are as previously described. Alkylheteroaryls can comprise a lower alkyl group. A non-limiting example of a suitable alkylheteroaryl group includes 2- methylpyridine. The bond to the parent moiety is through the heteroaryl.
- Cycloalkyl means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, and in another embodiment, about 5 to about 10 carbon atoms. Cycloalkyl rings can contain about 5 to about 7 ring atoms.
- the cycloalkyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above.
- suitable monocyclic cycloalkyls include cydopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
- Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbornyl, adamantyl and the like, as well as partially saturated species such as, for example, indanyl, tetrahydronaphthyl and the like.
- Cycloalkenyl means an unsaturated, non-aromatic mono- or multicyclic ring system having at least 1 carbon-carbon double bond, and comprising about 3 to about 10 carbon atoms, an in another embodiment, about 5 to about 10 carbon atoms.
- Cycloalkenyl rings can contain about 5 to about 7 ring atoms.
- the cycloalkenyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above.
- suitable monocyclic cycloalkenyls include cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and the like.
- Non-limiting examples of suitable multicyclic cycloalkyls include norbornenyl, adamantenyl and the like.
- Cycloalkylene means a difunctional group obtained by removal of a hydrogen atom from a cycloalkyl group that is defined above.
- cycloalkylene include , and
- Halogen or "halo” means fluorine, chlorine, bromine, or iodine. Preferred are fluorine, chlorine and bromine.
- Ring system substituent means a substituent attached to an aromatic or non- aromatic ring system which, for example, replaces an available hydrogen on the ring system.
- Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylene-aryl, alkylaryl, alkylene-heteroaryl, heteroaryl-alkenylene-, heteroaryl-alkynylene-, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aryl- alkoxy-, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aryl- alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aryl-alkylthio, heteroaryl-alkylthio, cycloalkyl, heterocyclyl,
- Ring system substituent may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system.
- Examples of such moiety are methylenedioxy, ethylenedioxy, -C(CH 3 ) 2 - and the like which form moieties such as, for example:
- Heterocyclyl or “heterocyclic” means a monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Heterocyclyls may be completely saturated, partially unsaturated, or aromatic. Aromatic heterocyclyls are termed "heteroaryl", as defined above. Preferred heterocyclyls contain about 5 to about 6 ring atoms.
- the prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom.
- Any -NH in a heterocyclyl ring may exist protected such as, for example, as an -N(Boc), -N(CBn), -N(Tos) group and the like; such protections are also considered part of this invention.
- the heterocyclyl can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein.
- the nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
- Non-limiting examples of suitable monocyclic heterocyclyl rings include saturated heterocyclyls, for example piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1 ,4-dioxanyl, . tetrahydrofuranyl, tetrahydrothiophenyl, lactams, lactones, and the like.
- Non-limiting examples of partially unsaturated monocyclic heterocyclyl rings include, for example, thiazolinyl, and the like. . . . .
- hetero-atom containing ring systems of this invention there are no hydroxy! groups on carbon atoms adjacent to a N, O or S, as well as there are no N or S groups on carbon adjacent to another heteroatom.
- N, O or S there are no N or S groups on carbon adjacent to another heteroatom.
- Alkynylalkyl means an alkynyl-alkyl- group in which the alkynyl and alkyl are as previously described. Alkynylalkyls can contain a lower alkynyl and a lower alkyl group. The bond to the parent moiety is through the alkyl.
- suitable alkynylalkyl groups include propargylmethyl.
- Heteroarylalkyl means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Heteroaralkyls can contain a lower alkyl group. Non- limiting examples of suitable aralkyl groups include pyridyl methyl, and quinolin-3- ylmethyl. The bond to the parent moiety is through the alkyl. "Hydroxyalkyl” means a HO-alkyl- group in which alkyl is as previously defined. Hydroxyalkyls can contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
- Acyl means an H-C(O)-, alkyl-C(O)- or cycloalkyl-C(O)-, group in which the . various groups are as previously described.
- the bond to the parent moiety is through the carbonyl.
- Acyls can contain a lower alkyl.
- suitable acyl groups include formyl, acetyl and propanoyl.
- Aroyl means an aryl-C(O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl.
- suitable groups include benzoyl and 1- naphthoyl.
- Alkoxy means an alkyl-O- group in which the alkyl group is as previously described.
- suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy.
- the bond to the parent moiety is through the ether oxygen.
- Aryloxy means an aryl-O- group in which the aryl group is as previously described.
- suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen.
- Aryl-alkyloxy (or arylalkoxy) means an aryl-alkyl-O- group in which the aryl- alkyl group is as previously described.
- suitable aryl-alkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy.
- the bond to the parent moiety is through the ether oxygen.
- Alkylthio means an alkyl-S- group in which the alkyl group is as previously described.
- suitable alkylthio groups include methylthio and ethylthio.
- the bond to the parent moiety is through the sulfur.
- Arylthio means an aryl-S- group in which the aryl group is as previously described.
- suitable arytthio groups include phenylthio and naphthylthio. The bond to the parent moiety is through the sulfur.
- Aryl-alkylthio (or arylalkylthio) means an aryl-alkyl-S- group in which the aryl- alkyl group is as previously described.
- aryl-alkylthio benzylthio.
- the bond to the parent moiety is through the sulfur.
- Alkoxycarbonyl means an alkyl-O-C(O)- group.
- suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl.
- the bond to the parent moiety is through the carbonyl.
- Aryloxycarbonyl means an aryl-O-C(O)- group.
- suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl. The bond to the parent moiety is through the carbonyl.
- Arylalkoxycarbonyl means an aryl-alkyl-O-C(O)- group.
- Non-limiting example of a suitable aralkoxycarbonyl group is benzyloxycarbonyl.
- the bond to the parent moiety is through the carbonyl.
- Alkylsulfonyl means an alkyl-S(O 2 )- group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.
- Arylsulfonyl means an aryl-S(O 2 )- group. The bond to the parent moiety is through the sulfonyl.
- substituted means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
- stable compound' or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
- optionally substituted means optional substitution with the specified groups, radicals or moieties. An optionally substituted moiety may be unsubstituted or substituted with one or more substituents.
- purified refers to the physical state of said compound after being isolated from a synthetic process or natural source or combination thereof.
- purified refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan, in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.
- metabolic rate enhancer refers to compounds which improve energy expenditure. It should also be noted that any carbon as well as heteroatom with unsatisfied " valencesirrthre textrschemes ⁇ iexamples ⁇ and ' Tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.
- protecting groups When a functional group in a compound is termed "protected", this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in Organic Synthesis (1991), Wiley, New York.
- any variable e.g., aryl, heterocycle, R 1 , etc.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- Prodrugs and solvates of the compounds of the invention are also contemplated herein.
- a discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press.
- the term "prodrug” means a compound (e.g, a drug precursor) that is transformed in vivo to yield a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in blood.
- CoA reductase inhibitor contains a carboxylic acid functional group
- a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (Ci-C 8 )alkyl, (C 2 -C-i2)alkanoyloxymethyl, 1- (alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl Raving from 5 to 10 carbon atoms, alKoxycarbbnyl ⁇ xymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms,
- a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (Ci-C 6 )alkanoyloxymethyl, 1-((d-C 6 )alkanoyloxy)ethyl, 1 -methyl-1 -((C T C ⁇ JalkanoyloxyJethyl, (C-i-CeJalkoxycarbonyloxymethyl, N-(Cn-C 6 )alkoxycarbonylaminomethyl, succinoyl, (Ci-C 6 )alkanoyl, ⁇ -amino(C 1 -C 4 )alkanyl, arylacyl and ⁇ -aminoacyl, or ⁇ -aminoacyl- ⁇ -aminoacyl, where each ⁇ -aminoacyl group is independently selected from the naturally occurring L-a group
- a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R-carbonyl, RO-carbonyl, NRR'-carbonyl where R and R' are each independently (C- ⁇ -Cio)alkyl, (C 3 -C 7 ) cycloalkyl, benzyl, or R-carbonyl is a natural ⁇ - aminoacyl or natural ⁇ -aminoacyl, -C(OH)C(O)OY 1 wherein Y 1 is H, (C-rC 6 )alkyt or benzyl, -C(OY 2 )Y 3 wherein Y 2 is (C 1 -C 4 ) alkyl and Y 3 is (d-CeJalkyl, carboxy (C-rC 6 )alkyl, amino(C-rC 4 )
- One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated TofmsT tl Sorvate"lnea1n ⁇ ⁇ a ' pfiysical ⁇ ' ssbl:ialioT ⁇ of a " compound of this invention with one or more solvent molecules.
- This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding.
- the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
- Solidvate encompasses both solution-phase and isolatable solvates.
- suitable solvates include ethanolates, methanolates, and the like.
- Hydrophilate is a solvate wherein the solvent molecule is H 2 O.
- One or more compounds of the invention may optionally be converted to a solvate.
- Preparation of solvates is generally known.
- M. Caira et a/ J. Pharmaceutical ScL, 93(3 ⁇ . 601-61 1 (2004) describes the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water. Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C.
- a typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods.
- Analytical techniques such as, for example I. R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
- an obese patient refers to a patient being overweight and having a body mass index (BMI) of 25 or greater.
- BMI body mass index
- an obese patient has a BMI of 25 or greater.
- an obese patient has a BMI from 25 to 30.
- an obese patient has a BMI greater than 30.
- an obese patient has a BMI greater than 40.
- obesity-related disorder refers to any disorder which results from a patient having a BMI of 25 or greater.
- Non-limiting examples of an obesity-related disorder include edema, shortness of breath, sleep apnea, skin disorders and high blood pressure.
- Effective amount or “therapeutically effective amount” is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the diseases or conditions noted below, and thus producing the desired therapeutic, amellbrativerinhibitory or preventative effect.
- appetite suppressant, metabolic rate enhancer, or HMG-CoA reductase inhibitor of the present invention can form salts which are also within the scope of this invention.
- Reference to the appetite suppressant or metabolic rate enhancer of the present invention herein is understood to include reference to salts thereof, unless otherwise indicated.
- the term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
- appetite suppressant, metabolic rate enhancer, or HMG-CoA reductase inhibitor of the present invention contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein.
- Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful.
- Salts of the appetite suppressant, metabolic rate enhancer, or HMG-CoA reductase inhibitor of the present invention may be formed, for example, by reacting the appetite suppressant, metabolic rate enhancer, HMG-CoA reductase inhibitor of the present invention with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
- Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like.
- Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like.
- Basic nitrogen-containing groups may be quartemized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g.
- dimethyl, diethyl, and dibutyl sulfates dimethyl, diethyl, and dibutyl sulfates
- long chain halides e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides
- aralkyl halides e.g. benzyl and phenethyl bromides
- esters of the appetite suppressant, metabolic rate enhancer, or HMG-CoA reductase inhibitor of the present invention include the following groups: (1 ) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n- propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, (Ci-C. ⁇ )alkyl, or (Ci-C 4 )alkoxy or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methane
- the appetite suppressant, metabolic rate enhancer, or HMG-CoA reductase inhibitor of the present invention may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the appetite suppressant, metabolic rate enhancer, or HMG-CoA reductase inhibitor of the present invention as well as mixtures thereof, including racemic mixtures, (and including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs) form part of the present invention.
- the present invention embraces all geometric and positional isomers, as well as enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers (e.g., substituted biaryls), and diastereomeric forms.
- enantiomeric forms which may exist even in the absence of asymmetric carbons
- rotameric forms e.g., atropisomers
- diastereomeric forms e.g., substituted biaryls
- the appetite suppressant, metabolic rate enhancer, or HMG-CoA reductase inhibitor of the present invention incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
- Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers.
- the chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.
- the use of the terms "salt”, “solvate”, “ester”, “prodrug” and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
- Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
- Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.
- an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
- Enantiomers can also be separated by use of a chiral HPLC column.
- the present invention also embraces isotopically-labeled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 0, 17 O, 31 P, 32 P, 35 S, 18 F, and 36 CI, respectively.
- Certain isotopically labeled compounds of the present invention are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
- Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an appropriate isotopically labeled reagent for a non-isotopically labeled reagent.
- Polymorphic forms of the appetite suppressant, metabolic rate enhancer, or HMG-CoA reductase inhibitor of the present invention, and of the salts, solvates, esters and prodrugs of the appetite suppressant or metabolic rate enhancer of the present invention, are intended to be included in the present invention.
- pharmaceutical composition is also intended to encompass both the bulk composition and individual dosage units comprised of more than one (e.g., two) pharmaceutically active agents such as, for example, a compound of the present invention and an additional agent selected from the lists of the additional agents described herein, along with any pharmaceutically inactive excipients.
- the bulk composition and each individual dosage unit can contain fixed amounts of the aforesaid "more than one pharmaceutically active agents".
- the bulk composition is material that has not yet been formed into individual dosage units.
- An illustrative dosage unit is an oral dosage unit such as tablets, pills and the like.
- the herein-described method of treating a patient by administering a pharmaceutical composition of the present invention is also intended to encompass the administration of the afore-said bulk composition and individual dosage units.
- the compounds of the present invention, or pharmaceutically acceptable salts, solvates, or esters thereof are useful in treating obesity or obesity related disorders.
- the appetite suppressant, metabolic rate enhancer, or HMG-CoA reductase inhibitor of the present invention, or pharmaceutically acceptable salts, solvates, or esters thereof can be administered in any suitable form, e.g., alone, or in combination with a pharmaceutically acceptable carrier, excipient or diluent in a pharmaceutical composition, according to standard pharmaceutical practice.
- the compounds of the present invention, or pharmaceutically acceptable salts, solvates, or esters thereof can be administered orally or parenterally, including intravenous, intramuscular, interperitoneal, subcutaneous, rectal, or topical routes of administration.
- compositions comprising the appetite suppressant or metabolic rate enhancer of the present invention, or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof can be in a form suitable for oral administration, e.g., as tablets, troches, capsules, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, syrups, or elixirs.
- Oral compositions may be prepared by any conventional pharmaceutical method, and may also contain sweetening agents, flavoring agents, coloring agents, and preserving agents.
- the amount of the appetite suppressant or metabolic rate enhancer of the present invention, or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, administered to a patient can be determined by a physician based on the age, weight, and response of the patient, as well as by the severity of the condition treated.
- the amount of the appetite suppressant or metabolic rate enhancer of the present invention, or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, administered to the patient can range from about 0.1 mg/kg body weight per day to about 60 mg/kg/d, preferably about 0.5 mg/kg/d to about 40 mg/kg/d.
- HMG CoA reductase inhibitor compounds useful in combination with the nicotinic acid receptor agonists of the present invention are lovastatin (for example MEVACOR® which is available from Merck & Co.), simvastatin (for example ZOCOR® which is available from Merck & Co.), pravastatin (for example PRAVACHOL® which is available from Bristol Meyers Squibb), atorvastatin (for example LIPITOR® which is available from Pfizer), atorvastatin, fluvastatin (for examples LESCOL® which is available from Novartis), cerivastatin, CI-981 , rivastatin (sodium 7-(4-fluorophenyl)-2,6-diisopropyl-5-methoxymethylpyridin-3-yl)-3,5- dihydroxy-6-heptanoate), rosuvastatin calcium (CRESTOR® from AstraZeneca Pharmaceuticals), pravastatin (such
- H 3 receptors have been implicated in thermogenesis regulation in rodents and in feeding behavior in humans.
- Various H 3 receptor antagonists/inverse agonists have been disclosed as useful for modulating histaminergic function, and thereby can be useful inlreating obesity and obesity-related conditions.
- H 3 receptor antagonists/inverse agonists have been disclosed in U.S.
- the present invention is directed to compositions comprising one or more metabolic rate enhancer which is an H 3 receptor antagonist/inverse agonist described generically (i.e., a compound according to Formula (I)-(VIII) as described herein) or specifically exemplified in U.S. 6,720,328, 6,849,621, 2004/0019099, 2004/0097483, 2004/0048843, or 2005/0113383 (each of which is herein incorporated by reference); and one or more appetite suppressant selected from the group consisting of a CBi antagonist (e.g., rimonabant), phentermine, sibutramine, and topiramate.
- a CBi antagonist e.g., rimonabant
- the present invention is directed to compositions comprising one or more H 3 receptor antagonist/inverse agonist; one or more appetite suppressant selected from the group consisting of a CB-i antagonist (e.g., rimonabant), phentermine, sibutramine, and topiramate; and one or more HMG-CoA reductase inhibitor.
- the present invention is directed to compositions comprising one or more H 3 receptor antagonist/inverse agonists and one or more antidiabetic agents.
- the compositions are useful for treating or preventing diabetes.
- diabetes There are two major forms of diabetes: Type I diabetes (also referred to as insulin-dependent diabetes or IDDM) and Type Il diabetes (also referred to as noninsulin dependent diabetes or NIDDM).
- IDDM insulin-dependent diabetes
- NIDDM noninsulin dependent diabetes
- the compositions are useful for treating Type I diabetes.
- the compositions are useful for treating Type Il diabetes.
- the anti-diabetic agent is an insulin sensitizer or a sulfonylurea.
- Non-limiting examples of sulfonylureas include glipizide, tolbutamide, glyburide, glimepiride, chlorpropamide, acetohexamide, gliamilide, gliclazide, glibenclamide and tolazamide.
- Insulin sensitizers include PPAR- ⁇ agonists described in detail above, preferably troglitazone, rosiglitazone, pioglitazone and englitazone; biguanidines such as metformin and phenformin; DPPIV inhibitors such as sitagliptin, saxagliptin, denagliptin and vildagliptin; PTP-1 B inhibitors; and glucokinase activators, ⁇ - Glucosidase inhibitors that can be useful in treating type Il diabetes include miglitol, acarbose, and voglibose.
- Hepatic glucose output lowering drugs include Glucophage and Glucophage XR.
- Insulin secretagogues include sulfonylurea and non- sulfonylurea drugs such as GLP-1 , exendin, GIP, secretin, glipizide, chlorpropamide, nateglinide, megtitinide, glibenclamide, repaglinide and glimepiride. Insulin includes all formualtions of insulin, including long acting and short acting forms of insulin.
- Non-limiting examples of anti-obesity agents useful in the present methods for treating diabetes include CB 1 antagonists or inverse agonists such as rimonabant, neuropeptide Y antagonists, MCR4 agonists, MCH receptor antagonists, histamnine H3 receptor antagonists or inverse agonists, leptin, appetite suppressants such as sibutramine, and lipase inhibitors such as xenical.
- CB 1 antagonists or inverse agonists such as rimonabant, neuropeptide Y antagonists, MCR4 agonists, MCH receptor antagonists, histamnine H3 receptor antagonists or inverse agonists, leptin, appetite suppressants such as sibutramine, and lipase inhibitors such as xenical.
- Non-limiting examples of antihypertensive agents useful in the present methods for treating diabetes include ⁇ -blockers and calcium channel blockers (for example diltiazem, verapamil, nifedipine, amlopidine, and mybefradil), ACE inhibitors (for example captopril, Hsinopril, enalapril, spirapril, ceranopril, zefenopril, fosinopril, cilazopril, and quinapril), AT-1 receptor antagonists (for example losartan, irbesartan, and valsartan), renin inhibitors and endothelin receptor antagonists (for example sitaxsentan).
- ⁇ -blockers and calcium channel blockers for example diltiazem, verapamil, nifedipine, amlopidine, and mybefradil
- ACE inhibitors for example captopril, Hsinopril, enalapril
- Non-limiting examples of meglitinides useful in the present methods for treating diabetes include repaglinide and nateglinide.
- Non-limiting examples of insulin sensitizers include biguanides, such as metformin and thiazolidinediones.
- the insulin sensitizer is a thiazolidinedione.
- Alpha-glucosidase inhibitors help the body to lower blood sugar by delaying the digestion of ingested carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following meals.
- Non-limiting examples of suitable alpha-glucosidase inhibitors include acarbose; miglitol; camiglibose; certain polyamines as disclosed in WO 01/47528 (incorporated herein by reference); voglibose.
- suitable peptides for increasing insulin production including amlintide (CAS Reg. No. 122384-88-7 from Amylin; pramlintide, exendin, certain compounds having Glucagon-like peptide-1 (GLP-1) agonistic activity as disclosed in WO 00/07617 (incorporated herein by reference).
- Non-limiting examples of orally administrable insulin and insulin containing compositions include AL-401 from Autoimmune, and the compositions disclosed in U.S.
- compositions comprising one or more H 3 receptor antagonist/inverse agonists and one or more anti-diabetic agents are useful for treating or preventing obesity or an obesity-related disorder.
- Anti-diabetic agents useful in the present methods for treating obesity or an obesity-related disorder include, but are not limited to the anti-diabetic agents listed above herein.
- the one or more H 3 receptor antagonist/inverse agonists and the one or more additional therapeutic agents can be administered simultaneously (at the same time, in a single dosage form or in separate dosage forms) or sequentially (first one and then another, etc... over a period of time) in any order.
- the H 3 antagonists/inverse agonists of the present invention can have a structure according to Formula (I):
- Non-limiting examples of compounds of Formula (I) include:
- the H 3 antagonists/inverse agonists of the present invention can have a structure according to Formula (II):
- Non-limiting examples of compounds of Formula (II) include:
- the H3 antagonists/inverse agonists of the present invention can have a structure according to Formula (III):
- Non-limiting examples of compounds of Formula (III) include:
- R, R , R , Z, and R 6 are as shown in the following Table:
- R, R 3 , Z, and R 6 are as defined in the following Table:
- R is as defined in the following Table:
- R 3 and R are as defined in the following Table:
- R 1 -X-, Z, R 3 , and R 2 are defined as shown in the following Table:
- R, M 1 , Y, and R 2 are defined as shown in the following Table:
- the H 3 antagonists/inverse agonists of the present invention can have a structure according to Formula (IV):
- Non-limiting examples of compounds of Formula (IV) include:
- R, (R 26 ) ⁇ , Y, Z, and R 2 are as defined in the following Table:
- R, (R26 ⁇ )k, Y, Z, and R 2 are as defined in the following Table:
- R, (R ) ⁇ , Y, Z, and R are as defined in the following Table:
- R (R >26 ) ⁇ , Y, r, p, Z, and R are defined as in the following Table:
- R 1 is defined as shown in the following Table:
- R >1 , D R3 , and R are defined as shown in the following Table:
- R 3 and R 2 are defined as shown in the following Table:
- R, R 20 , and R 2 are defined as shown in the following Table:
- t e 3 antagonists nverse agonists of the present invention can have a structure according to Formula (V):
- Non-limiting examples of compounds of Formula (V) include:
- R is as defined in the following Table:
- R is as defined in the following Table:
- R, R 8 and R 2 are as defined in the following Table:
- the H 3 antagonists/inverse agonists of the present invention can have a structure according to Formula (Vl):
- Non-limiting examples of compounds of Formula (Vl) include:
- R, R 3 , Z and R 6 are as shown in the following table:
- R is as shown in the following table:
- R, R 25 , A, R 3 , and R 2 are as shown in the following table:
- R 1 -X-, Z, R 3 , and R 2 are as shown in the following table:
- R, M 1 , Y, and R 2 are as shown in the following table:
- the H 3 antagonists/inverse agonists of the present invention can have the following structure:
- t he H 3 antagonists/inverse agonists of the present invention can have the following Formula (VII): as described in U.S. Provisional Application No. 60/692,110, filed June 20, 2005, and which is herein incorporated by reference in its entirety.
- Non-limiting examples of compounds of Formula (VII) include:
- H 3 antagonists/inverse agonists of the present invention can have the following Formula (VIII):
- Non-limiting examples of compounds of Formula (VIII) include:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06847740A EP1965862A2 (en) | 2005-12-21 | 2006-12-18 | Combination of an h3 antagonist/inverse agonist and an appetite suppressant |
BRPI0620386-8A BRPI0620386A2 (en) | 2005-12-21 | 2006-12-18 | composition comprising the combination of an h3 antagonist / inverse agonist and an appetite suppressant and use of said composition |
JP2008547391A JP2009521445A (en) | 2005-12-21 | 2006-12-18 | Combination of H3 antagonist / inverse agonist and appetite suppressant |
CA002634235A CA2634235A1 (en) | 2005-12-21 | 2006-12-18 | Combination of an h3 antagonist/inverse agonist and an appetite suppressant |
AU2006331994A AU2006331994A1 (en) | 2005-12-21 | 2006-12-18 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant |
NO20083204A NO20083204L (en) | 2005-12-21 | 2008-07-18 | Combination of an H3 antagonist / inverse agonist and an appetite suppressant |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75232305P | 2005-12-21 | 2005-12-21 | |
US60/752,323 | 2005-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007075555A2 true WO2007075555A2 (en) | 2007-07-05 |
WO2007075555A3 WO2007075555A3 (en) | 2007-12-21 |
Family
ID=38110672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/048223 WO2007075555A2 (en) | 2005-12-21 | 2006-12-18 | Combination of an h3 antagonist/inverse agonist and an appetite suppressant |
Country Status (14)
Country | Link |
---|---|
US (1) | US20070142369A1 (en) |
EP (1) | EP1965862A2 (en) |
JP (1) | JP2009521445A (en) |
KR (1) | KR20080081321A (en) |
CN (1) | CN101378807A (en) |
AR (1) | AR058122A1 (en) |
AU (1) | AU2006331994A1 (en) |
BR (1) | BRPI0620386A2 (en) |
CA (1) | CA2634235A1 (en) |
NO (1) | NO20083204L (en) |
PE (1) | PE20071162A1 (en) |
TW (1) | TW200730168A (en) |
WO (1) | WO2007075555A2 (en) |
ZA (1) | ZA200806068B (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008108957A2 (en) * | 2007-03-02 | 2008-09-12 | Schering Corporation | Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain |
WO2008108958A2 (en) * | 2007-03-02 | 2008-09-12 | Schering Corporation | Benzimidazole derivatives and methods of use thereof |
WO2010101246A1 (en) * | 2009-03-05 | 2010-09-10 | 塩野義製薬株式会社 | Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US8895551B2 (en) | 2009-04-02 | 2014-11-25 | Shionogi & Co., Ltd. | Acrylamide compounds and the use thereof |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
CN109311888A (en) * | 2016-06-10 | 2019-02-05 | 法国施维雅药厂 | New acyclic derivatives, preparation method and the pharmaceutical composition containing them |
WO2020002611A1 (en) | 2018-06-28 | 2020-01-02 | Phenex-Fxr Gmbh | Novel lxr modulators with bicyclic core moiety |
CN113166097A (en) * | 2018-12-03 | 2021-07-23 | 默克专利股份公司 | 4-heteroarylcarbonyl-N- (phenyl or heteroaryl) piperidine-1-carboxamides as tankyrase inhibitors |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200922582A (en) * | 2007-08-20 | 2009-06-01 | Organon Nv | N-benzyl, N'-arylcarbonylpiperazine derivatives |
US8314091B2 (en) | 2007-08-20 | 2012-11-20 | Msd Oss B.V. | N-benzyl,N'-arylcarbonylpiperazine derivatives |
WO2009135842A1 (en) * | 2008-05-08 | 2009-11-12 | Evotec Neurosciences Gmbh | Azetidines and cyclobutanes as histamine h3 receptor antagonists |
TW201006816A (en) * | 2008-05-15 | 2010-02-16 | Organon Nv | Hexafluoroisopropanol derivatives |
US20110130385A1 (en) * | 2008-07-23 | 2011-06-02 | De Lera Ruiz Manuel | Bicyclic Heterocylic Derivatives and Methods of Use |
EP2391616B1 (en) * | 2009-01-28 | 2016-03-30 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds and methods for using the same |
EP2395987A1 (en) | 2009-02-12 | 2011-12-21 | Coöperatieve Mirzorg U.A., Arnhem | Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders |
PL2473049T3 (en) | 2009-09-04 | 2019-07-31 | Biogen Ma Inc. | Bruton's tyrosine kinase inhibitors |
CA2785536C (en) * | 2009-12-30 | 2018-02-27 | Arqule, Inc. | Substituted imidazopyridinyl-aminopyridine compounds |
CA2801074A1 (en) | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
CN103748093B (en) | 2011-06-24 | 2016-06-01 | 艾科尔公司 | Imidazopyridyl-the aminopyridine compounds being replaced |
US8815854B2 (en) | 2011-06-24 | 2014-08-26 | Arqule, Inc. | Substituted imidazopyridinyl compounds |
CN102416015B (en) * | 2011-08-23 | 2013-02-27 | 南京正宽医药科技有限公司 | Composition containing statins and application thereof |
AR091273A1 (en) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | PYRIMIDINYL TIROSINE KINASE INHIBITORS |
CN105566321B (en) * | 2014-10-29 | 2020-04-21 | 广东东阳光药业有限公司 | Heteroaromatic compounds and their use in medicine |
TW201706265A (en) | 2015-03-09 | 2017-02-16 | 必治妥美雅史谷比公司 | Lactams as inhibitors of ROCK |
WO2018017153A1 (en) | 2016-07-21 | 2018-01-25 | Biogen Ma Inc. | Succinate forms and compositions of bruton's tyrosine kinase inhibitors |
WO2018232264A1 (en) * | 2017-06-15 | 2018-12-20 | The Board Of Regents Of The University Of Oklahoma | Benzamide derivatives for inhibiting endoplasmic reticulum (er) stress |
WO2020054788A1 (en) * | 2018-09-13 | 2020-03-19 | キッセイ薬品工業株式会社 | Imidazopyridinone compound |
NL2022615B1 (en) | 2019-02-21 | 2020-08-31 | Patrick Alexander Unger | Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight |
SG11202110742TA (en) | 2019-04-02 | 2021-10-28 | Aligos Therapeutics Inc | Compounds targeting prmt5 |
CA3169000A1 (en) * | 2020-03-11 | 2021-09-16 | Hideki Takeuchi | Crystal of imidazopyridinone compound or salt thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030130253A1 (en) * | 2001-09-14 | 2003-07-10 | Dorwald Florencio Zaragoza | Novel aminoazetidine,-pyrrolidine and -piperidine derivatives |
WO2003088967A1 (en) * | 2002-04-18 | 2003-10-30 | Schering Corporation | (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists |
WO2007002057A1 (en) * | 2005-06-20 | 2007-01-04 | Schering Corporation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists |
WO2007001975A1 (en) * | 2005-06-20 | 2007-01-04 | Schering Corporation | Piperidine derivatives useful as histamine h3 antagonists |
WO2007035703A1 (en) * | 2005-09-20 | 2007-03-29 | Schering Corporation | 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4820850A (en) * | 1987-07-10 | 1989-04-11 | Merck & Co., Inc. | Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof |
US4916239A (en) * | 1988-07-19 | 1990-04-10 | Merck & Co., Inc. | Process for the lactonization of mevinic acids and analogs thereof |
US5869479A (en) * | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
EP0920864A1 (en) * | 1997-12-03 | 1999-06-09 | Pfizer Products Inc. | Combination therapy including a specific beta-3 agonist and an anorectic agent |
JP2002534511A (en) * | 1999-01-18 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | Substituted imidazoles, their preparation and use |
US6437147B1 (en) * | 2000-03-17 | 2002-08-20 | Novo Nordisk | Imidazole compounds |
PE20020507A1 (en) * | 2000-10-17 | 2002-06-25 | Schering Corp | NON-IMIDAZOLE COMPOUNDS AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR |
CN1298715C (en) * | 2001-03-13 | 2007-02-07 | 先灵公司 | Non-imidazole compounds as histamine H3 antagonists |
US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
US20030186963A1 (en) * | 2001-09-14 | 2003-10-02 | Dorwald Florencio Zaragoza | Substituted piperidines |
US7220735B2 (en) * | 2002-04-18 | 2007-05-22 | Schering Corporation | Benzimidazolone histamine H3 antagonists |
US7105505B2 (en) * | 2002-04-18 | 2006-09-12 | Schering Corporation | Benzimidazole derivatives useful as histamine H3 antagonists |
DK1539742T3 (en) * | 2002-06-24 | 2006-12-27 | Schering Corp | Indole derivatives useful as histamine H3 antagonists |
US6673529B1 (en) * | 2002-07-11 | 2004-01-06 | Eastman Kodak Company | Method for making tabular grain silver halide emulsion |
US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
US20040224952A1 (en) * | 2003-05-07 | 2004-11-11 | Cowart Marlon D. | Fused bicyclic-substituted amines as histamine-3 receptor ligands |
AR041089A1 (en) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | PROCEDURE AND PHARMACEUTICAL COMPOSITIONS TO TREAT ATEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED AFFECTIONS |
-
2006
- 2006-12-18 WO PCT/US2006/048223 patent/WO2007075555A2/en active Application Filing
- 2006-12-18 BR BRPI0620386-8A patent/BRPI0620386A2/en not_active IP Right Cessation
- 2006-12-18 CN CNA2006800531644A patent/CN101378807A/en active Pending
- 2006-12-18 PE PE2006001622A patent/PE20071162A1/en not_active Application Discontinuation
- 2006-12-18 JP JP2008547391A patent/JP2009521445A/en active Pending
- 2006-12-18 AU AU2006331994A patent/AU2006331994A1/en not_active Abandoned
- 2006-12-18 KR KR1020087017435A patent/KR20080081321A/en not_active Application Discontinuation
- 2006-12-18 CA CA002634235A patent/CA2634235A1/en not_active Abandoned
- 2006-12-18 US US11/640,729 patent/US20070142369A1/en not_active Abandoned
- 2006-12-18 EP EP06847740A patent/EP1965862A2/en not_active Withdrawn
- 2006-12-19 TW TW095147674A patent/TW200730168A/en unknown
- 2006-12-19 AR ARP060105616A patent/AR058122A1/en not_active Application Discontinuation
-
2008
- 2008-07-11 ZA ZA200806068A patent/ZA200806068B/en unknown
- 2008-07-18 NO NO20083204A patent/NO20083204L/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030130253A1 (en) * | 2001-09-14 | 2003-07-10 | Dorwald Florencio Zaragoza | Novel aminoazetidine,-pyrrolidine and -piperidine derivatives |
WO2003088967A1 (en) * | 2002-04-18 | 2003-10-30 | Schering Corporation | (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists |
WO2007002057A1 (en) * | 2005-06-20 | 2007-01-04 | Schering Corporation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists |
WO2007001975A1 (en) * | 2005-06-20 | 2007-01-04 | Schering Corporation | Piperidine derivatives useful as histamine h3 antagonists |
WO2007035703A1 (en) * | 2005-09-20 | 2007-03-29 | Schering Corporation | 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist |
Non-Patent Citations (1)
Title |
---|
HANCOCK A A ET AL: "Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists" EXPERT OPINION ON INVESTIGATIONAL DRUGS 2005 UNITED KINGDOM, vol. 14, no. 3, March 2005 (2005-03), pages 223-241, XP002450211 ISSN: 1354-3784 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008108957A2 (en) * | 2007-03-02 | 2008-09-12 | Schering Corporation | Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain |
WO2008108958A2 (en) * | 2007-03-02 | 2008-09-12 | Schering Corporation | Benzimidazole derivatives and methods of use thereof |
WO2008108957A3 (en) * | 2007-03-02 | 2009-02-05 | Schering Corp | Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain |
WO2008108958A3 (en) * | 2007-03-02 | 2009-05-07 | Schering Corp | Benzimidazole derivatives and methods of use thereof |
JP5642661B2 (en) * | 2009-03-05 | 2014-12-17 | 塩野義製薬株式会社 | Piperidine and pyrrolidine derivatives having NPYY5 receptor antagonistic activity |
JPWO2010101246A1 (en) * | 2009-03-05 | 2012-09-10 | 塩野義製薬株式会社 | Piperidine and pyrrolidine derivatives having NPYY5 receptor antagonistic activity |
US8889674B2 (en) | 2009-03-05 | 2014-11-18 | Shionogi & Co., Ltd. | Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism |
WO2010101246A1 (en) * | 2009-03-05 | 2010-09-10 | 塩野義製薬株式会社 | Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism |
US8895551B2 (en) | 2009-04-02 | 2014-11-25 | Shionogi & Co., Ltd. | Acrylamide compounds and the use thereof |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US8889190B2 (en) | 2013-03-13 | 2014-11-18 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US10363224B2 (en) | 2013-03-13 | 2019-07-30 | Upsher-Smith Laboratories, Llc | Extended-release topiramate capsules |
US10172878B2 (en) | 2013-03-15 | 2019-01-08 | Upsher-Smith Laboratories, Llc | Extended-release topiramate capsules |
US9555005B2 (en) | 2013-03-15 | 2017-01-31 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
CN109311888A (en) * | 2016-06-10 | 2019-02-05 | 法国施维雅药厂 | New acyclic derivatives, preparation method and the pharmaceutical composition containing them |
CN109311888B (en) * | 2016-06-10 | 2021-09-14 | 法国施维雅药厂 | Piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them |
WO2020002611A1 (en) | 2018-06-28 | 2020-01-02 | Phenex-Fxr Gmbh | Novel lxr modulators with bicyclic core moiety |
US11618747B2 (en) | 2018-06-28 | 2023-04-04 | Orsobio, Inc. | LXR modulators with bicyclic core moiety |
US11970484B2 (en) | 2018-06-28 | 2024-04-30 | Orsobio, Inc. | LXR modulators with bicyclic core moiety |
CN113166097A (en) * | 2018-12-03 | 2021-07-23 | 默克专利股份公司 | 4-heteroarylcarbonyl-N- (phenyl or heteroaryl) piperidine-1-carboxamides as tankyrase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
PE20071162A1 (en) | 2007-11-30 |
NO20083204L (en) | 2008-09-22 |
BRPI0620386A2 (en) | 2011-12-20 |
WO2007075555A3 (en) | 2007-12-21 |
CN101378807A (en) | 2009-03-04 |
CA2634235A1 (en) | 2007-07-05 |
JP2009521445A (en) | 2009-06-04 |
ZA200806068B (en) | 2009-07-29 |
EP1965862A2 (en) | 2008-09-10 |
TW200730168A (en) | 2007-08-16 |
AR058122A1 (en) | 2008-01-23 |
KR20080081321A (en) | 2008-09-09 |
AU2006331994A1 (en) | 2007-07-05 |
US20070142369A1 (en) | 2007-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007075555A2 (en) | Combination of an h3 antagonist/inverse agonist and an appetite suppressant | |
CA2627623C (en) | Methods for inhibiting protein kinases | |
TW202144345A (en) | Kras mutant protein inhibitors | |
US20100144591A1 (en) | Benzimidazole derivatives and methods of use thereof | |
US20100093692A1 (en) | Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain | |
US8735604B2 (en) | Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use | |
JP2012508692A (en) | Inhibitors of fatty acid binding protein (FABP) | |
JP2019504901A (en) | Positive allosteric modulator of muscarinic acetylcholine receptor M1 | |
WO2007056468A1 (en) | Methods for inhibiting protein kinases | |
US20110224187A1 (en) | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof | |
US8470773B2 (en) | Thiophenes as glucagon receptor antagonists, compositions, and methods for their use | |
US20110207734A1 (en) | Azine Derivatives and Methods of Use Thereof | |
JP2020526557A (en) | Antagonist of muscarinic acetylcholine receptor M4 | |
MX2014004254A (en) | Carbamate/ urea derivatives containing piperidin and piperazin rings as h3 receptor inhibitors. | |
US20110245267A1 (en) | Piperidine and piperazine derivatives and methods of use thereof | |
US20120225885A1 (en) | Imidazole derivatives and methods of use thereof | |
US20110130385A1 (en) | Bicyclic Heterocylic Derivatives and Methods of Use | |
WO2010056630A1 (en) | Triazolopyrimidinones and methods of use thereof | |
JP2010540523A (en) | Oxypiperidine derivatives as histamine receptor antagonists | |
US20220356176A1 (en) | Kv11.1-3.1 INHIBITING METHODS AND COMPOSITIONS | |
JP2006501244A (en) | Selective D1 / D5 receptor antagonists for the treatment of obesity and CNS disorders | |
JP2006501244A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006847740 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 569221 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008501486 Country of ref document: PH Ref document number: 2634235 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008547391 Country of ref document: JP Ref document number: 2006331994 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/008336 Country of ref document: MX Ref document number: 08064503 Country of ref document: CO Ref document number: 3160/CHENP/2008 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006331994 Country of ref document: AU Date of ref document: 20061218 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087017435 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680053164.4 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: PI0620386 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080623 |